-
Human Synthetic Amyloid Beta Peptide 1-42 (HFIP treated)
Human Synthetic Amyloid Beta Peptide 1-42 (HFIP treated)
- 中文名称：
- Human Synthetic Amyloid Beta Peptide 1-42 (HFIP treated)
- 英文名称：
- Human Synthetic Amyloid Beta Peptide 1-42 (HFIP treated)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA254100
- 规格：
- 0.1 mg|0.5 mg|1 mg|2x1 mg|3x1 mg
- 保存建议：
- Store at -80 degree C
- 货期：
- 6-8周
- 纯度：
- >98%
- 产品形式：
- Dry powder. See "Other Resources" for re-suspension instructions/protocol.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Our amyloid beta peptide 1-42 (Abeta42) is produced synthetically and treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) prior to drying which breaks down pre-formed fibrils and monomerizes the peptide, as previously published (1,2). Upon resuspension in DMSO/dH2O, our Abeta42 presents as a monomeric peptide without fibrils when observed under TEM, AFM and on a Western Blot with an anti-amyloid beta antibody. In contrast to AB42 oligomer and fibril constructs, our Abeta42 monomers were not toxic to primary rat cortical neurons.In the brain, amyloid beta peptide (Abeta) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of Abeta plaques in the brain is considered a hallmark of Alzheimer's disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (3). Soluble Abeta oligomers isolated from the brains of AD patients or those generated in vitro potently impaired synapse structure and function (4). Abeta oligomers generated in vitro were toxic to PC12 cells (2) and SH-SY5Y cells (5). Abeta was demonstrated to interact with tauopathies to affect neurodegeneration in AD patients (6) and accumulations of Abeta were shown to be associated with lower survival rates in Parkinson's disease patients with dementia (7).
